Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C

被引:42
|
作者
Wu, J
Chen, S [1 ]
Gui-Qiang, W
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Infect Dis, Harbin 150086, Peoples R China
[2] PeiKing Univ, Hosp 1, Dept Infect Dis, PeiKing, Peoples R China
关键词
fatty liver; genotype; hepatitis C; insulin; sustained virologic response;
D O I
10.1111/j.1478-3231.2006.01219.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: Hepatic steatosis is a histological feature in patients with chronic hepatitis C (CHC) and adversely affects the virologic response rates to anti-hepatitis C virus (HCV) therapy. The aim of this study is to investigate whether the fatty liver and related factors have impact on the efficacy in CHC treated with peginterferon and ribavirin, and the associations between HCV genotyping and fatty liver. Methods: Ninety-eight patients received subcutaneously 180 mu g peginterferon alpha-2a once a week plus ribavirin. HCV genotypes and the levels of plasma insulin of patients were measured. Fatty liver was detected by B ultrasound. The body mass index (BMI), waist-to-hip ratio (WHR) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. Results: Among 98 CHC patients, 38 (38.8%) were infected with genotype 1; 44 (44.9%) with genotype 2; 13 (13.3%) with genotype 3; 3 (3.0%) with indeterminate genotype. The prevalence of fatty liver was 10.5%, 11.4%, 38.5% in patients infected with HCV genotype 1, 2, 3, respectively, which suggested that the distribution of fatty liver in different HCV genotypes was imbalanced (chi(2)=6.758, P=0.034). In univariate analysis, the efficacy of combination therapy was significantly associated with BMI (P=0.011), WHR (P=0.024), the levels of plasma insulin (P=0.001), genotype (P=0.036), presence of fatty liver (P=0.028), treatment dosage and duration (P=0.012) and HOMA-IR (P=0.002). With binary logistic regression analysis, the plasma insulin levels and HOMA-IR showed independent predictors to the efficacy of antiviral therapy. Conclusion: The prevalence of fatty liver in HCV genotype 3 was markedly higher than that of other genotypes. The BMI, WHR, the levels of plasma insulin, genotype, presence of fatty liver, treatment dosage and duration and HOMA-IR were associated with the sustained virologic response. The level of plasma insulin and HOMA-IR were independent factors for predicting effect of antiviral therapy.
引用
收藏
页码:166 / 172
页数:7
相关论文
共 50 条
  • [1] Antiviral therapy for chronic hepatitis C in 2014
    Nookathota, Manogna
    Mukherjee, Sandeep
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (04) : 499 - 505
  • [2] Use of Antiviral Therapy in Patients with Chronic Hepatitis C and its Adverse Effects
    Sajad, Qamar
    Ali, Adnan
    Malik, Yasir Raheem
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2020, 14 (03): : 1266 - 1268
  • [3] Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C
    Suda, Goki
    Kudo, Mineo
    Nagasaka, Atsushi
    Furuya, Ken
    Yamamoto, Yoshiya
    Kobayashi, Tomoe
    Shinada, Keisuke
    Tateyama, Miki
    Konno, Jun
    Tsukuda, Yoko
    Yamasaki, Kazushi
    Kimura, Megumi
    Umemura, Machiko
    Izumi, Takaaki
    Tsunematsu, Seiji
    Sato, Fumiyuki
    Terashita, Katsumi
    Nakai, Masato
    Horimoto, Hiromasa
    Sho, Takuya
    Natsuizaka, Mitsuteru
    Morikawa, Kenichi
    Ogawa, Koji
    Sakamoto, Naoya
    JOURNAL OF GASTROENTEROLOGY, 2016, 51 (07) : 733 - 740
  • [4] Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
    Chang, Jin Won
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    Kim, Seung Up
    GUT AND LIVER, 2021, 15 (01) : 117 - 127
  • [5] Antiviral therapy: chronic hepatitis C
    Heathcote, E. Jenny
    JOURNAL OF VIRAL HEPATITIS, 2007, 14 : 82 - 88
  • [6] The influence of hepatic steatosis on the success of antiviral therapy for chronic hepatitis C
    Preveden, Tomislav
    Ruzic, Maja
    Pete, Maria
    VOJNOSANITETSKI PREGLED, 2017, 74 (04) : 317 - 322
  • [7] Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C
    Jimenez Macias, Fernando Manuel
    Barrero Alor, Fatima
    Casado Monge, Pedro German
    Ramos Lora, Manuel
    Pujol de la Llave, Emilio
    Ruiz-Frutos, Carlos
    MEDICINA CLINICA, 2015, 144 (12): : 536 - 543
  • [8] The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C
    Nakamura, H
    Uyama, H
    Enomoto, H
    Kishima, Y
    Yamamoto, M
    Yoshida, K
    Okuda, Y
    Hirotani, T
    Kuroda, T
    Ito, H
    Matsuda, M
    Terabayashi, M
    Noguchi, S
    HEPATO-GASTROENTEROLOGY, 2003, 50 (49) : 222 - 226
  • [9] Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C
    Benhammou, Jihane N.
    Moon, Andrew M.
    Pisegna, Joseph R.
    Su, Feng
    Vutien, Philip
    Moylan, Cynthia A.
    Ioannou, George N.
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (07) : 2394 - 2406
  • [10] Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation
    Gurusamy, Kurinchi Selvan
    Tsochatzis, Emmanuel
    Toon, Clare D.
    Davidson, Brian R.
    Burroughs, Andrew K.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):